Source briefingOctober 9, 2026Investigations
Opinion/decision on a Paediatric investigation plan (PIP): Nilemdo, bempedoic acid (ETC-1002), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Metabolism and nutrition disorders, PIP number: EMA/PE/0000238109

Source briefing · A concise briefing based on one linked source. It is intentionally shorter than a full FreedomWitness Evidence Engine analysis.
What the source reports
Opinion/decision on a Paediatric investigation plan (PIP): Nilemdo, bempedoic acid (ETC-1002), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Metabolism and nutrition disorders, PIP number: EMA/PE/0000238109
Evidence note: At this stage FreedomWitness is presenting what this source reports. This briefing does not independently prove every underlying claim and should be read together with the original material.
Source & verification
Primary source: What's new · October 9, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

EudraGMDP database
What is established The EudraGMDP database is an established European Union (EU) information system managed by the European Medicines Agency (EMA). It serves as…

Antimicrobial resistance in the EU/EEA (EARS-Net) – Annual Epidemiological Report for 2025
Evidence Dossier: Antimicrobial Resistance Trends in the EU/EEA 2025 Antimicrobial Resistance Trends in the EU/EEA: Evidence from the 2025 EARS-Net Report What is established…

Rapid risk assessment – Carbapenem-resistant Enterobacterales, fourth update
Evidence Dossier: Carbapenem-resistant Enterobacterales (CRE) in the EU/EEA – Latest Scientific Assessment What is established Carbapenem-resistant Enterobacterales (CRE), which include bacteria such as Klebsiella…